Skip to main content
Caplight Logo









PamGene International BV

PamGene International BV

Private
's-HertogenboschHealthcare & Life Scienceshttps://pamdx.com/

Last Round

Series A

Apr 16, 2026

Total Funding Raised

$23.5M

Company Overview

PamGene International BV is a biotechnology company that provides a peptide-based microarray technology for kinase activity profiling to support drug development and diagnostics.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales, Services & Consulting, Hardware + Subscription

AI Layer

Application

Keywords

kinase activity profilingfunctional proteomicsbiomarker discoveryin-vitro diagnosticsIVDmicroarray technologypatient stratificationdrug development toolscontract research organizationCROimmuno-oncologypersonalized medicinecellular signalingproteomics platform3D microarrayIOpener test

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PamGene International BV Comparables

Compare PamGene International BV with similar companies based on industry and business-model similarity.

PamGene International BV comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pepscope
81%
RayBiotech
79%
Biosynth
79%

PamGene International BV Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 16, 2026
GrantJun 27, 2023

PamGene International BV Investors

Notable investors and investment history

PamGene International BV investors
InvestorRounds
European Innovation Council FundGrant
Myosotis InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 15, 2025

    Grew 16% QoQ, from 37 to 43 employees.

  • Jun 27, 2023

    Secured $8.2M from the European Innovation Council Fund.

PamGene International BV Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PamGene International BV Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PamGene International BV's valuation, stock price, and market status.

Firmographic Details

Headquarters's-Hertogenbosch
Employee Range48
Year Founded1999
Last FundingApr 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?